What Happens When You Stop Mounjaro or Wegovy? Weight Regain, Returning Hunger and Planning Ahead
You have worked hard to make changes, seen progress and perhaps started to feel more comfortable in everyday life. Then a new question appears: what happens if you stop taking Mounjaro or Wegovy?
You might be approaching a weight-management goal, thinking about cost, experiencing side effects or simply wondering how long treatment should continue. It is understandable to want a clearer picture.
Hunger can return and weight regain is common, but neither means you have failed.
Understanding the evidence and arranging support can help you approach the next stage with realistic expectations.
Here, we explore what may change after treatment ends, what research can tell us and what to discuss before making a decision.
Why can hunger return after treatment stops?
Wegovy contains semaglutide, which acts on GLP-1 receptors. Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors. Their effects include helping regulate appetite and food intake. [1,2]
As medicine levels fall after stopping, the support they provide can diminish. You may feel hungry sooner, find larger portions appealing or notice that thoughts about food occupy more of your day.
The medicines do not disappear immediately after the final injection. Tirzepatide has a half-life of approximately five days and injectable semaglutide approximately one week. These figures describe how medicine levels fall, rather than predicting the day your appetite will change. [1,2]
Everyone's experience is different. A gradual change in hunger is possible, and an exact timetable cannot be promised.
Does returning hunger mean I have lost my willpower?
No. Appetite is influenced by biological signals as well as routine, sleep, stress, emotions and the food around us. It is not simply a test of determination.
Many people describe frequent thoughts about eating as 'food noise'. This is an everyday expression rather than a diagnosis. If those thoughts return, it can feel unsettling after months of feeling less preoccupied with food.
Try to describe the change without judging yourself. Are you physically hungry between meals? Skipping lunch? Eating in response to stress? Waking hungry at night?
Different patterns may need different support. Persistent distress, loss-of-control eating or increasingly restrictive behaviour deserves professional help, rather than another set of strict food rules.
What did the Wegovy withdrawal research find?
The STEP 1 extension followed a subset of adults without diabetes after treatment with weekly semaglutide 2.4 mg ended. The lifestyle intervention used during the main trial also stopped. [3]
In the semaglutide group, average weight loss during the initial 68 weeks was 17.3%. Over the following year, participants regained 11.6 percentage points of body weight—approximately two-thirds of the weight previously lost. They remained, on average, 5.6% below their starting weight.
These are group averages, not a prediction for every patient. The extension included 327 participants overall and was exploratory.
Importantly, this study cannot isolate the effect of stopping medication from stopping the structured lifestyle intervention. It also does not directly describe every Wegovy formulation or dose used today.
What happened when Mounjaro's ingredient was withdrawn?
SURMOUNT-4 studied adults with obesity, or overweight with a weight-related complication, without diabetes. Participants initially received tirzepatide for 36 weeks, reaching a maximum tolerated dose of 10 or 15 mg. [4]
Those who completed that phase lost an average of 20.9% of their starting weight. They were then randomly allocated to continue tirzepatide or switch to placebo for another 52 weeks.
The placebo group gained an average of 14.0% relative to their weight at the point of switching. Those continuing treatment lost a further 5.5%. Diet and physical activity support continued.
That 14.0% is not '14% of the weight previously lost': the denominator is different. The trial demonstrates substantial average regain after withdrawal, without establishing what every person will experience or which stopping strategy is best.
What does the newer 2026 review add?
A systematic review published in The BMJ in January 2026 brought together 37 studies involving 9,341 participants across different weight-management medicines. It found that weight regain after stopping was common. [5]
Across the medicines studied, the estimated average regain rate was around 0.4 kg per month. The researchers projected a return to starting weight in about 1.7 years.
The word 'projected' matters. That longer-term estimate came from modelling the available follow-up, rather than observing every participant until that point. Follow-up was often short, and the studies differed.
The figures should not become a countdown or an individual forecast. They strengthen the case for ongoing care and realistic planning, while leaving uncertainty about the best way to support each person after treatment.
Will I definitely regain all the weight?
No one can promise your individual outcome. Research describes average patterns, and the amount and pace of regain vary.
It would be misleading to say that everyone returns to exactly the same weight. It would also be misleading to promise that following a meal plan or exercising consistently will prevent regain completely.
Weight management is influenced by health, treatment history, circumstances and the support available. People may need different combinations of ongoing care.
If your weight starts increasing, bring it into the conversation early. You deserve a review of what is happening and what options are suitable, without being told that you simply need to try harder.
Does reaching my target weight mean I should stop?
Reaching a goal is a good opportunity to review treatment. It does not automatically answer whether medication should continue, change or end.
A weight-management review should consider more than the scales: treatment benefit, side effects, nutrition, physical function, medical conditions, preferences and the practicalities of ongoing care all matter.
Weight maintenance and medication withdrawal are different discussions. Some people may benefit from continued treatment, while others need or choose to stop. The plan should reflect an individual assessment.
Ask your prescriber what maintenance means for you, how often it will be reviewed and which changes should prompt contact. Avoid using someone else's dose or experience as a template.
Do I need to reduce the dose gradually?
There is no single stopping or tapering schedule that this article can recommend for everyone. The withdrawal studies above do not establish that gradually reducing doses prevents weight regain.
If you are considering stopping, ask your prescriber to explain the options and uncertainties.
Your reason for stopping matters, particularly if pregnancy, significant side effects or another medical issue is involved.
Do not create your own schedule by extending injection intervals, splitting doses or using unofficial 'click-counting' instructions. Such approaches should not be presented as proven maintenance methods.
A planned discussion is useful, but urgent safety advice takes priority. Follow your medicine leaflet and seek medical help if you have symptoms that require treatment to be stopped or reviewed immediately.
What should I discuss before my final dose?
Start with why you want to stop and what concerns you most. Cost, side effects, pregnancy plans and treatment fatigue are all worth discussing openly.
Ask which health markers need monitoring, who will provide follow-up and what to do if hunger or weight changes become difficult. If the medicine also manages diabetes, involve your diabetes team: blood glucose and other treatment may need review.
Bring a list of medicines and supplements, your recent weight pattern and a realistic description of eating and activity. Mention any difficulties keeping meals regular or getting enough nourishment.
Before leaving, make sure you know how to contact the relevant team. A clear next step is more useful than a vague instruction to 'keep an eye on things'.
Build an eating routine you can live with
When hunger increases, responding with severe restriction can make everyday eating more stressful. Aim for a manageable routine and discuss individual dietary needs with a registered dietitian or clinician.
Include foods you enjoy alongside sources of protein, fibre and other nutrients. For example, you might choose yoghurt with oats and fruit, beans on wholemeal toast, or fish, tofu or chicken with vegetables and potatoes.
These are flexible meal ideas, not a fixed calorie prescription. Portions and choices should fit your appetite, preferences, allergies and health needs.
Planning a few reliable meals can help on busy days. Keep convenient options available so that a disrupted afternoon does not leave you without food until late evening.
Supplements cannot replace adequate meals, and no 'GLP-1 booster' should be assumed to reproduce the effects of prescribed treatment.
Keep movement practical—and include strength
Activity is worth maintaining for health, mobility and wellbeing, even when the number on the scales changes. It should not become a punishment for eating.
The NHS advises adults to aim for at least 150 minutes of moderate activity a week, or 75 minutes of vigorous activity, alongside strengthening activities on at least two days. Build up gradually and adapt activity to your abilities. [6]
Walking, swimming, dancing and cycling can all contribute. Strength work might involve resistance bands, suitable weights or bodyweight exercises.
If illness, pain or disability limits activity, ask what is safe and realistic. A manageable routine that fits your week is more useful than an ambitious plan you cannot sustain.
Exercise supports health, but should not be sold as a guarantee against weight regain after medication withdrawal.
Agree follow-up rather than going it alone
NICE's quality standard says people stopping weight-management medicines should receive advice and support to maintain changes and improve health and wellbeing. It describes regular feedback and monitoring for at least one year. [7]
That provides a useful framework for discussing aftercare. Ask which reviews are available through your provider or local services and how to access additional support if needed.
An agreed plan might cover eating routines, activity, emotional wellbeing and selected health checks. The frequency and content should reflect your circumstances.
A simple 'if–then' plan can make action easier: 'If hunger makes it difficult to manage meals, I will contact my clinician rather than repeatedly skipping food.'
The existence of guidance does not mean every service offers the same programme. Confirm arrangements before treatment ends.
Monitor trends without letting the scales take over
Agree a monitoring approach that feels useful rather than distressing. If weighing is appropriate, use a consistent routine and look at the trend over time rather than reacting to a single reading.
Day-to-day changes can reflect factors such as fluid, bowel contents and the menstrual cycle. One higher number does not tell the whole story.
Notice energy, strength, sleep and how manageable eating feels too. Your clinician may recommend checks such as blood pressure or blood glucose according to your history.
If weighing triggers anxiety, restriction or compulsive checking, say so. Monitoring can be adapted.
A sustained upward trend is a reason to review the plan, not to blame yourself or make unsupervised medication changes.
Can I restart if I change my mind?
Restarting needs a fresh conversation with your prescriber. Do not assume that your previous dose is suitable after a treatment gap.
Tell them when you last took the medicine, which dose you used, why you stopped and whether your health or other medicines have changed. Eligibility, tolerability and the current product instructions all need consideration.
A plan for one missed dose is not necessarily appropriate after several weeks without treatment. Do not double doses, overlap medicines or use leftover supplies without checking.
The same applies to switching between Mounjaro, Wegovy and other products. There is no simple dose-for-dose conversion for you to calculate yourself.
If cost or supply is driving the change, raise that early so the available options can be reviewed safely.
When should I seek medical advice urgently?
Do not wait for a routine appointment if you have severe, persistent abdominal pain, particularly if it spreads to your back or occurs with vomiting. Seek urgent medical assessment and follow the safety instructions for your medicine. [1,2]
Repeated vomiting, inability to keep fluids down, very little urine or marked dizziness also needs prompt assessment. Symptoms should not automatically be attributed to stopping treatment.
If you have diabetes and develop concerning high or low blood glucose readings or symptoms, follow your agreed diabetes plan and seek advice.
For planned pregnancy, discuss stopping well in advance. If you become pregnant during treatment, contact your prescriber promptly and follow the leaflet advice. Stopping and follow-up should fit the reason for the change.
Planning the next chapter with support
Stopping Mounjaro or Wegovy can bring changes in appetite, weight and how you feel about food. Research helps explain why ongoing support matters, but cannot predict your individual journey.
Try to plan before the final dose where possible. Know who to contact, what follow-up is available and how you will respond if things become difficult.
At AJ Hill Aesthetics, we encourage you to raise these questions during your reviews. Explain your priorities and concerns so the next steps can be discussed with your prescribing clinician.
Your progress is about more than a single number. You deserve practical advice and respectful care, whether treatment continues or stops.
This article provides general information, mainly concerning weekly injectable treatments. It does not replace an individual assessment or the patient information leaflet for your specific medicine.
Related reading
Sources and further reading
Information checked: 19 October 2026.
